Rucaparib shows clinical benefit in pancreatic cancer patients with BRCA mutation

Posted by on June 4, 2016 5:19 pm
Categories: health

The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation.

Leave a Reply

Your email address will not be published. Required fields are marked *